ReviewLe infezioni in medicina2021
Mucormycosis in COVID-19: A systematic review of literature.
Review in Le infezioni in medicina, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 27 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
27 citing papers in PubMed, 49 citations in OpenAlex.
- Clinical profile and outcome of COVID-19 associated mucormycosis in Shiraz, South Iran: a longitudinal study.Iranian journal of microbiology · 2026Article
- Correlation Between Endoscopic and Radiological Data in Rhino-Orbital-Cerebral Mucormycosis (ROCM).Cureus · 2026Article
- COVID-19-Associated Mucormycosis: Identifying Mortality Predictors in a Retrospective Cohort Study.Open forum infectious diseases · 2025Article
- Comparative Mortality and Risk Analysis in Mucormycosis Cases: Pre-Pandemic Versus COVID-19 Association.Indian journal of otolaryngology and head and neck surgery : official publication of the Association of Otolaryngologists of India · 2025Article
- A Case Report of Acute Lymphoblastic Leukemia Complicated by Naso-Ophthalmic Mucormycosis.Cureus · 2025Article
- Impact of COVID-19 on mucormycosis presentation and laboratory values: A comparative analysis.PloS one · 2025Article
- Epidemiology of mucormycosis in COVID-19 patients in northwest Iran:Current medical mycology · 2025Article
- Mucormycosis, the Black Fungus in the Post-COVID-19 Pandemic: A Case Report with Review of Literature.Cureus · 2024Article
- Corona-Associated Mucormycosis: Case Series Reports and Review of the Literature.Journal of fungi (Basel, Switzerland) · 2024Article
- Genetic Basis for Mucormycosis Progression in COVID-19 Patients: From Susceptibility to Severity.Infectious diseases & immunity · 2024Review
- COVID-19-Associated Rhino-Orbital Mucormycosis: Histological and Electron Microscopy Characteristics.Diagnostics (Basel, Switzerland) · 2024Article
- COVID-19-Associated Rhinocerebral Mucormycosis, an Incidental Finding or a Matter of Concern - Mixed-Method Systematic Review.Infection and drug resistance · 2024Review
- Proven Cutaneous Mucormycosis in a COVID-19 Patient: A Case Report and Literature Review.Iranian journal of pathology · 2024Article
- Mucormycosis: A Case Series.Cureus · 2023Article
- COVID-19 associated mold infections: Review of COVID-19 associated pulmonary aspergillosis and mucormycosis.Journal of microbiology, immunology, and infection = Wei mian yu gan ran za zhi · 2023Review
- COVID-19 as a trigger of Guillain-Barré syndrome: A review of the molecular mechanism.Immunity, inflammation and disease · 2023Review
- A case of COVID-19-associated mucormycosis due to Lichtheimia ramosa.Journal of clinical laboratory analysis · 2023Article
- Rise of mucormycosis during the COVID-19 pandemic and the challenges faced.Current medical mycology · 2023Review
- Article
- Vitamin A Deficiency, COVID-19, and Rhino-Orbital Mucormycosis (Black Fungus): An Analytical Perspective.Advances in experimental medicine and biology · 2023Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors at 2 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Coronavirus disease 2019 (COVID-19) is an acute viral illness caused by severe acute respiratory syndrome coronavirus-2 (SARS-CoV-2). Opportunistic infections such as mucormycosis have been reported among COVID-19 patients particularly in South Asian countries during the second wave of this pandemic. It is necessary to re-evaluate any changes in traditional risk factors associated with mucormycosis such as diabetes mellitus, organ transplant, etc in the precedent of ongoing COVID-19 pandemic. We conducted a systematic review using electronic databases. A total of 115 COVID-19 patients who were diagnosed with mucormycosis were included in this study. Diabetes mellitus was the most common co-morbidity with 77.1%, followed by hypertension (29.5%) and renal disease (14.3%). 55.2% of the patients had received dexamethasone for COVID-19 infection. Ten patients (11.5%) had received tocilizumab. Sinuses were the most common site of mucormycosis among COVID-19 patients at 79.4% with maxillary sinus (47.4%) being most commonly infected. Orbits were the second most prevalent site at 56.7% and lungs were infected with mucor at 11.3%. The mean duration between the diagnosis of COVID-19 infection and mucormycosis was 16.15 days (range 2-90 days). Cavernous sinus was either infiltrated or encased in 14 patients (14.4%). Cerebral involvement was seen in terms of abscess, infarcts, or edema in 12 patients (12.4%). Only 76 patients had data on the outcomes, out of which 37 (48.7%) patients had died. Diabetes mellitus is still the most common co-morbidity similar to non-COVID-19 patients. More than 90% of the patients with COVID-19 infection had received steroids. Complications such as cavernous sinus thrombosis, cerebral infarcts, abscesses were common. Indiscriminate use of steroids in patients needs to be avoided and focus needs to be put on tight blood sugar control in diabetic patients. Studies are needed to confirm the role of the SARS-CoV-2 virus in causing immune dysfunction and mucormycosis.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.